Results 141 to 150 of about 5,691,277 (301)

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Cannabis products: medical use

Revista da Associação Médica Brasileira, 2023
César Eduardo Fernandes, José Eduardo Lutaif Dolci, Leonardo Sobral Navarro, Marcelo Allevato, Clóvis Francisco Constantino, Rodrigo Pastor Alves Pereira, Carlos Roberto de Mello Rieder, Flávia Torino, Wanderley Marques Bernardo, Antônio Geraldo da Silva   +9 more
openaire   +3 more sources

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

Addiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor, Jessica Shields, Asiya Hamid, Eleanor Holman, Hannah Biggs, Sarah Minty, Jamie Pearce, Allison Ford   +7 more
wiley   +1 more source

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy

Brain and Behavior
Background A third of epilepsy patients fail to enter seizure remission despite optimal therapeutic management. Cannabis‐based medicinal products (CBMPs) have shown promise as a potential therapy.
Isaac Cowley, Simon Erridge, Arushika Aggarwal, Lilia Evans, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, Augustin Iqbal, James J Rucker, Mark W Weatherall, Mikael H Sodergren   +11 more
doaj   +1 more source

Bill to legalise medicinal cannabis shouldn't be passed - health committee.

, 2017
Health committee member Kate O’Connell said that an opportunity was lost to make cannabis a medical product..........
Ni Aodha, Grainne
core  

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

Brain and Behavior
Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia.
Kavyesh Vivek, Zekiye Karagozlu, Simon Erridge, Carl Holvey, Ross Coomber, James J. Rucker, Mark W. Weatherall, Mikael H Sodergren   +7 more
doaj   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source